Estrella Immunopharma annual r&d spending
2022
2023
2024
2024
2025
Estrella Immunopharma R&D Spending Growth & History (ESLA)
Estrella Immunopharma's r&d spending was $10.2M for fiscal 2025.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.2M | $7.4M | +258.52% |
| 2024 · Dec 31 | 2024-12-31 | $2.9M | — | — |
| 2024 · Jun 30 | 2024-06-30 | $4.1M | −$6.3M | −60.68% |
| 2023 | 2023-06-30 | $10.5M | $9.1M | +652.37% |
| 2022 | 2022-06-30 | $1.4M | — | — |
Estrella Immunopharma quarterly r&d spending
Q3.22
Q4.22
Q1.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | −$3.3M | −69.95% |
| Q1 2026 | 2026-03-31 | $1.4M | −$9,913 | −0.70% |
| Q4 2025 | 2025-12-31 | $25,414 | — | — |
| Q3 2025 | 2025-09-30 | $4.2M | $1.3M | +46.94% |
| Q2 2025 | 2025-06-30 | $4.7M | $1.1M | +32.21% |
| Q1 2025 · Mar 31 | 2025-03-31 | $1.4M | $1.4M | +5540.75% |
| Q1 2025 · Sep 30 | 2024-09-30 | $2.8M | $2.3M | +484.53% |
| Q4 2024 | 2024-06-30 | $3.5M | $910,303 | +34.81% |
| Q3 2024 | 2024-03-31 | $25,000 | −$2.6M | −99.05% |
| Q2 2024 | 2023-12-31 | $75,459 | −$2.5M | −97.11% |
| Q1 2024 | 2023-09-30 | $483,466 | −$2.1M | −81.44% |
| Q4 2023 | 2023-06-30 | $2.6M | — | — |
| Q1 2023 | 2023-03-31 | $2.6M | — | — |
| Q4 2022 | 2022-12-31 | $2.6M | — | — |
| Q3 2022 | 2022-09-30 | $2.6M | — | — |
Estrella Immunopharma r&d spending trends
Between the periods ended 2022-06-30 and 2025-12-31, Estrella Immunopharma's r&d spending increased from $1.4M to $10.2M, a change of $8.9M. The latest reported quarter, Q2 2026, shows $1.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗